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Abstract: 
 
Dendrimers have potential for delivering chemotherapeutic drugs to solid tumours via 
the enhanced permeation and retention (EPR) effect. The impact of conjugation of 
hydrophobic anticancer drugs to hydrophilic PEGylated dendrimer surfaces, however, 
has not been fully investigated. The current study has therefore characterised the 
effect on dendrimer disposition of conjugating α-carboxyl protected methotrexate 
(MTX) to a series of PEGylated 3H-labelled poly-L-lysine dendrimers ranging in size 
from generation 3 (G3) to 5 (G5) in rats. Dendrimers contained 50% surface PEG and 
50% surface MTX. Conjugation of MTX generally increased plasma clearance when 
compared to conjugation with PEG alone. Conversely, increasing generation reduced 
clearance, increased metabolic stability and reduced renal elimination of the 
administered radiolabel. For constructs with molecular weights >20 kDa increasing 
the molecular weight of conjugated PEG also reduced clearance and enhanced 
metabolic stability but had only a minimal effect on renal elimination. Tissue 
distribution studies revealed retention of MTX conjugated smaller (G3-G4) PEG570 
dendrimers (or their metabolic products) in the kidneys. In contrast, the larger G5 
dendrimer was concentrated more in the liver and spleen. The G5 PEG1100 dendrimer 
was also shown to accumulate in solid Walker 256 and HT1080 tumours and 
comparative disposition data in both rats (1 to 2% dose/g in tumour) and mice (11% 
dose/g in tumour) are presented. The results of this study further illustrate the 
potential utility of biodegradable PEGylated poly-L-lysine dendrimers as long-
circulating vectors for the delivery and tumour-targeting of hydrophobic drugs. 
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Introduction: 
 
Several approaches have been explored in an attempt to achieve site specific 
chemotherapy, including localised drug administration1, antibody mediated targeting2, 
and exploitation of abnormalities in the vascular structure and lymphatic drainage of 
solid tumours via the enhanced permeation and retention (EPR) effect3. Tumour 
targeting via the EPR effect has received considerable attention3 and a large range of 
nanoparticular carriers (liposomes, polymeric micelles, nanoparticles) and 
macromolecules (proteins, polymers, dendrimers) have been evaluated for their 
potential to enhance the biodistribution of chemotherapeutics to solid tumours3-6.  
A number of commonalities are evident in delivery systems that achieve 
effective EPR in tumour tissue. These include a requirement for molecular size (or 
particle size in the case of a colloidal carrier) to be larger than the threshold for renal 
filtration and the presentation of a hydrophilic interaction surface to the biological 
environment to reduce enzymatic cleavage or phagocytic abstraction3, 4, 7. In turn, 
these properties provide for extended circulation times after intravenous 
administration and the opportunity for enhanced extravasation at sites of enhanced 
vascular permeability (such as that within many solid tumours). Stealth liposomes 
with hydrodynamic diameters of 100-200 nm have been shown to provide some 
degree of tumour targeting and to release encapsulated drug over extended periods of 
time4. Indeed doxorubicin encapsulated in a PEGylated liposome (Doxil®) is 
currently used to treat a range of solid tumours including breast and ovarian 
carcinomas, prostate cancer and Karposi’s sarcoma8. A number of reports have also 
described improved chemotherapy and decreased systemic toxicity via the 
conjugation of anticancer drugs, including doxorubicin or methotrexate (MTX), to 
Page 4 of 48
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  5, 18/05/2009 
polymers9-16. Several PEGylated dendronised polymers have also been examined as 
drug delivery systems that may improve the circulation time, tumour targeting, anti-
tumour efficacy and systemic toxicity of surface conjugated drugs.12, 17-21 In each of 
these cases, surface PEGylation was used to reduce accumulation of the dendrimers 
into reticuloendothelial organs and increase plasma circulation times such that tumour 
targeting via EPR could be enhanced. The influence of PEG load and size on the 
plasma residence of dendrimers has previously been characterised18, 22, however, the 
impact of drug conjugation on the stealth effects imparted by PEGylation has not been 
evaluated. This is potentially significant since many anticancer drugs are hydrophobic 
and as such their presence is likely to change the surface characteristics and in vivo 
behaviour of the PEGylated dendrimer carriers. 
In the current study therefore, G2 to G4 poly-lysine dendrimers were capped 
with succinimyldipropyldiamine (SuN(PN)2, abbreviated to SPN in subsequent 
dendrimer nomanclature) derived wedges comprising 50% PEG (570-2300 Da) and 
50% methotrexate to form G3 to G5 PEGylated, MTX-linked dendrimers and their 
intravenous pharmacokinetics, plasma stability and tissue deposition profiles 
examined. The symmetrical analogue of lysine was employed in an attempt to 
potentially enhance metabolic stability (and therefore circulation time) since previous 
studies have shown a marked increase in metabolic stability for L-lysine dendrimer 
cores when capped with a non-natural layer such as D-lysine23. In these studies, 
methotrexate was linked via a stable amide linker since use of a cleavable linkage 
would preclude accurate investigation of the effects of drug conjugation on the 
pharmacokinetic properties of the intact dendrimer due to liberation of drug and 
exposure of the linker and dendrimer scaffold by enzymatic degradation. The largest 
G5 dendrimer (containing a 50% PEG1100 surface) was also examined for potential 
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  6, 18/05/2009 
tumour accumulation via the EPR effect and a comparative study of tumour uptake in 
rats and mice conducted. In addition, since the dendrimers employed in the current 
study were prepared using a symmetrical analogue of lysine in the final lysine 
generation (succinimyldipropyldiamine, Figure 1) the pharmacokinetics and 
disposition have been compared to the equivalent all-L-lysine (ie. natural lysine) fully 
PEGylated dendrimers described previously.  
 
Methods: 
 
Materials 
Buffer reagents were purchased from Aldrich and were used without further 
purification. N-(benzyloxycarbonyl)-3-bromopropylamine and mono-BOC-1,3-
diamino propane were purchased from High Force Research Ltd (Durham, England). 
Unlabelled lysine for synthesis was purchased from Bachem (Bunbendorf, 
Switzerland). Soluene-350 and Starscint were purchased from Packard Biosciences 
(Meriden, CT). Heparin (10,000 U/ml) was obtained from Faulding (SA, Australia). 
Saline was from Baxter Healthcare (NSW, Australia). Medium 199, Minimum 
Essential Medium (MEM) with Earles salts, trypsin-EDTA (0.25%) and non-essential 
amino acids (NEAA) were purchased from Sigma (NSW, Australia). Hanks Balanced 
Salt Solution (HBSS), foetal bovine serum (FBS), horse serum, Glutamax and 
penicillin-streptomycin were from Gibco (NY, USA). Cell culture flasks (75 cm2) 
were from Corning (NY, USA). Isopropyl alcohol was AR grade and was purchased 
from Mallinckrodt Chemicals (Phillipsburg, USA). All other solvents were HPLC 
grade and were used without any further purification. (L)-(4,5-3H)-lysine (1 mCi/ml) 
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  7, 18/05/2009 
was purchased from MP Biomedicals (Irvine, CA, USA). Monodisperse PEG570NHS, 
PEG1100NHS and PEG2300NHS were purchased from Quanta BioDesign, Ltd (USA). 
 
Synthesis of radiolabelled dendrimers. 
The tritium radiolabel was incorporated using a lysine moiety that contained 
tritium labels at the γ and δ positions and in all cases the tritium labelled lysine was 
used in the outermost lysine layer of the dendrimer scaffold. A similar nomenclature 
for the dendrimers has been described previously23, but briefly, dendrimers generated 
using an outer generation of SuN(PN)2 are represented as GX(SPN)-(PEGY)Z(drug)Z 
or GX(SPN)-(PEGY)Z, where X represents the final dendrimer generation (including 
the outer SPN layer), SPN is abbreviated notation for SuN(PN)2 and refers to an outer 
layer composed of succinimyldipropyldiamine (a symmetrical analogue of lysine), Y 
represents the MW of the PEG chain and Z represents the number of PEG and drug 
molecules attached to the surface. Fully PEGylated dendrimers containing all L-lysine 
scaffolding which were previously referred to as LysX(PEGY)2X, where X is the 
number of lysines in the outer generation and Y is the PEG MW22, have in the current 
paper been referred to as GX(Lys)-(PEGY)Z, in order to be consistent with the 
notation used for dendrimers composed with an outer generation of SuN(PN)2. In 
these studies, methotrexate (MTX) was chosen as a model hydrophobic anticancer 
drug. For the purposes of this study the free carboxylic acid group of MTX was tert-
butyl protected in an attempt to prevent the potential complicating effects of MTX 
interaction with folate receptors and therefore additional effects on clearance and 
biodistribution patterns beyond that resulting generically from drug conjugation. 
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The 3H-labelled dendrimers synthesised were: 
G3(SPN)-(PEG570)32,      100% PEGylated 
G4(SPN)-(PEG570)64, 
G3(SPN)-(PEG570)8(MTX)8,  
G3(SPN)-(PEG1100)8(MTX)8,  
G4(SPN)-(PEG570)16(MTX)16,  
G4(SPN)-(PEG1100)16(MTX)16,     50% PEGylated,  
G4(SPN)-(PEG2200)16(MTX)16,     50% MTX 
G5(SPN)-(PEG570)32(MTX)32 and  
G5(SPN)-(PEG1100)32(MTX)32 . 
 
The preparation of the dendrimers is described in detail in the supplementary 
information available at http://www.pubs.acs.org. The SuN(PN)2 wedges were 
prepared according to Scheme 1. Mono-BOC-1,3-diaminopropane was mono-
alkylated with N-(benzyloxycarbonyl)-3-bromopropylamine, then reacted with 
succinic anhydride to give the carboxylic acid. This was then protected as the ethyl 
ester, the Cbz group removed, and replaced with a PEG group. The BOC group was 
then removed and replaced by MTX(-α-OtBu)24. Lastly the ethyl ester was removed, 
and the wedge coupled to the radiolabelled dendrimer (Scheme 2). 
The specific radioactivity of the dendrimers was determined by dilution of a 
known mass of dendrimer (in triplicate) in 1 ml Starscint, followed by scintillation 
counting using a Packard Tri-Carb 2000CA Liquid Scintillation Analyser (Meriden, 
CT). Specific activity was typically within the range of 0.5 to 1 µCi/mg. 
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The particle size and polydispersity index (PDI) of dendrimers with identical 
molecular weight, but composed of generation 4 all L-lysine (G4(Lys)-(PEG570)32) or 
with an outer layer of SuN(PN)2 (G4(SNP)-(PEG570)32) were compared by photon 
correlation spectroscopy using a Nano ZS Zetasizer (Malvern Instruments, 
Worestershire, UK25). Dendrimers were dissolved to 1 mg/ml in isotonic saline and 
filtered through a 20 nm membrane (Milipore, Melbourne, Australia) prior to analysis. 
The refractive index for the protein standard was 1.450. 
 
Animals 
Sprague Dawley rats (SD male, 270-350 g) were supplied by Monash 
University (Melbourne, Victoria). Rats were maintained on a 12 hour light/dark cycle 
and were fed standard rodent chow prior to surgery. Food was withheld after surgery 
and for 8 hours post IV dose but water was available at all times.  
Nude athymic rats (male, 6-7 weeks of age) and SCID mice (female, 6 weeks 
of age) were purchased from the Australian Research Centre (Perth, WA) and were 
housed in microisolators (Australian Research Centre, WA) maintained at 22 °C on a 
12 hour light/dark cycle. Since the athymic rats and SCID mice were not subjected to 
surgical implantation of cannulae or routine blood sampling, animals were provided 
food and water at all times. 
All animal experiments were approved by the Victorian College of Pharmacy 
Animal Ethics Committee, Monash University (Melbourne, Victoria). 
 
Cell culture conditions 
 Walker 256 cells (rat breast carcinoma) and HT1080 cells (human 
adenocarcinoma) were purchased from ECACC (Salisbury, UK). Walker 256 cells 
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  10, 18/05/2009 
were grown in 75cm2 flasks in medium 199 supplemented with 5% FBS, 2 mM 
Glutamax and 1% penicillin-streptomycin in a humidified atmosphere of 5% CO2 and 
37°C. Cells were passaged 1:4 using 0.25% trypsin-EDTA twice per week. HT1080 
cells were grown in 75cm2 flasks in MEM supplemented with 2 mM Glutamax, 1% 
NEAA, 10% FBS and 1% penicillin-streptomycin in a humidified atmosphere as 
above. Cells were passaged 1:5-6 using 0.25% trypsin-EDTA 3 times per week. Both 
cells lines tested negative for mycoplasma contamination. 
 
Determination of intravenous plasma pharmacokinetics in Sprague Dawley rats 
SD rats were cannulated via the right jugular vein and carotid artery under 
isoflurane anaesthesia as described previously23. After surgery, rats were transferred 
to metabolism cages (which allowed collection of urine and faeces), and were allowed 
to recover overnight prior to administration of 1 ml of dendrimer solution (in 50 mM 
PBS, pH 7.4) via the jugular vein to provide a final dose of 5 mg dendrimer/kg. Prior 
to dosing, a blank blood sample (150 µl) was collected via the carotid artery into a 
heparinised (10 U) Eppendorf tube. Animals were dosed with each dendrimer solution 
as an infusion over 1.5 min. Dendrimer remaining in the cannula at the end of the 
infusion was flushed through the cannula with a further 200 µl of heparinised saline (2 
U heparin/ml) over 30 sec. A zero time point sample (150 µl, t=0) was immediately 
collected via the carotid artery cannula to facilitate estimation of Cp0 and Vc. Further 
blood samples (150-200 µl) were collected at t=0, 10, 20, 30, 45, 60, 90, 120, 180, 
240, 360, 480, 1440 and 1800 min and stored in heparinised (100 U) Eppendorf tubes. 
Additional blood samples were collected at 48, 54, 72, 78, 96, 102, 120, 126, 144, and 
168 h for longer circulating dendrimers. Whole blood samples were centrifuged 
(3,500 × g) for 5 min to isolate plasma. Plasma samples (50-100 µl) were then mixed 
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  11, 18/05/2009 
with 1 ml Starscint in 6 ml scintillation vials and counted for 3H-content as described 
above.  
 
Urinary excretion and biodistribution of 3H dendrimers in Sprague Dawley rats 
Urine was collected and subsequently analysed for 3H-content over time 
periods of 0-8, 8-24, 24-30 (or 48 for longer circulating dendrimers), 48-72, 72-96 and 
96-120 (168 for longer circulating dendrimers) hours. Aliquots (100 – 200 µl) of the 
urine collected over these time periods were analysed for 3H by mixing with 1-2 ml of 
Starscint and scintillation counted as described above. Total urinary output was 
calculated from the 3H in each aliquot and the measured volume of urine collected 
over the collection period. 
For the biodistribution studies, rats were euthanised by intravenous infusion of 
Lethabarb (1 ml of 325 mg/ml pentobarbitone sodium) at various times post dose 
depending on the timescale of circulation. Thus, animals administered G4(SPN)-
(PEG570)32, G3(SPN)-(PEG570)8(MTX)8, G3(SPN)-(PEG1100)8(MTX)8 and G4(SPN)-
(PEG570)16(MTX)16 were euthanised at 30 h post dose, G5(SPN)-(PEG570)64 at 78 h 
post dose, G4(SPN)-(PEG1100)16(MTX)16 at 96 h post dose, G4(SPN)-
(PEG2200)16(MTX)16 and G5(SPN)- (PEG570)32(MTX)32 at 120 h post dose and 
G5(SPN)-(PEG1100)32(MTX)32 at 168 h post dose. The major organs (liver, kidneys, 
spleen, pancreas, heart, lungs, brain) were removed, weighed and homogenised in 5-
10 ml Milli-Q water using a Waring mini-blender (Extech Equipment Pty. Ltd, 
Boronia, Australia) for 5 × 10 second intervals. The homogenates were processed and 
the 3H-content of the homogenates determined as described previously23.  
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Size exclusion chromatography of plasma, urine and kidney homogenate 
Arterial blood and urine collected at various time points were analysed by size 
exclusion chromatography to identify the tritiated species present. Prior to injection 
onto the column (Superdex 75, Amersham Biosciences, NJ, USA) plasma and urine 
samples were diluted 1:1 in mobile phase (50 mM PBS + 0.3 M NaCl, pH 3.5) where 
tritium counts were high enough to facilitate column separation and scintillation 
counting of collected fractions. Sample aliquots (100-200 µl) were then injected onto 
the column and eluted with mobile phase at 0.5 ml/min using a Waters 590 pump 
(Millipore Corporation, Milford, MA, USA). Fractions were collected every 1 min 
using a Gilson FC10 fraction collector (John Morris Scientific Pty. Ltd., Melbourne, 
Australia) and mixed with 3 ml Starscint in 6 ml scintillation vials prior to 
scintillation counting for 3H-content as described above. 
Kidney homogenate (obtained from rats administered G3(SPN)-
(PEG570)8(MTX)8, G3(SPN)-(PEG1100)8(MTX)8 and G4(SPN)-(PEG570)8(MTX)8) was 
also analysed by size exclusion chromatography. Approximately 1 ml of homogenate 
was collected into separate Eppendorf tubes and centrifuged at 10,000 × g for 5 min to 
remove large particulate material. The supernatant was then filtered through a 0.22 
µm polypropylene membrane (13 mm filter unit, Lida Manufacturing Corp., WI, 
USA) to remove insoluble particles. The filtered supernatant was mixed 1:1 with 
mobile phase and 200 µl was injected onto the column. Fractions were collected and 
analysed as described above. 
 
Tumour deposition of G5(SPN)-(PEG1100)32(MTX)32 in Nude rats and  SCID mice 
 Walker 256 and HT1080 cells were used between passages 5 and 10. For 
induction of solid tumours in nude rats, cells were passaged using trypsin-EDTA, 
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washed once in HBSS and resuspended to 3 × 107 cells per ml in HBSS. A 200 µl 
suspension of Walker 256 or HT1080 cells (6 × 106 cells in total) was then injected 
into the right flank of rats (n=6-7 rats for each cell line) using a 25G needle. Tumour 
growth was monitored with a pair of callipers every 2 days (Equation 1 below). When 
tumours reached approximately 1000 mm3 (approximately 17 days for Walker 256 
tumours and 10 days for HT1080 tumours) rats were anaesthetised with 3% isoflurane 
and injected with 1 mg of G5(SPN)-(PEG1100)32(MTX)32 in a final volume of 200 µl 
of sterile saline intravenously via the tail vein using a 27G needle. Rats were then 
killed after collection of blood via cardiac puncture under isoflurane anaesthesia via 
direct cardiac administration of 1 ml Lethabarb 2 or 5 days after IV dosing and 
tumour, liver, spleen, muscle (from the left thigh) and fat (from the left dorsal region) 
collected for biodistribution analysis as described above. 
Equation 1:                            )(
3
4)( 22 bammvolume ×Π=  
                         where a = longest radius (mm), b = shortest radius (mm) 
 Since tumour deposition studies are typically not conducted in rats, for 
comparison of tissue deposition data in rats to the more commonly used mouse model, 
a suspension of 1 × 107 HT1080 cells per ml of HBSS (as above) was prepared and 1 
million cells (in a final volume of 100 µl) injected into the left flank of 6 mice using a 
25G needle. Tumour growth was monitored every 2 days. When tumours reached 
approximately 100 mm3 (Equation 1, approximately 23 days) mice were injected with 
0.15 mg of G5(SPN)-(PEG1100)32(MTX)32 intravenously via the tail vein using a 27G 
needle. After 2 days, mice were injected IP with 100 µl Lethabarb and blood (via 
cardiac puncture) collected prior to death. Tumour, liver, spleen, pancreas, kidneys, 
heart, lungs, muscle (from the right thigh) and fat (from the right dorsal region) were 
excised after death and collected into 20 ml scintillation vials. Whole organs and 
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blood (100 µl) were solubilised in 4 ml of 1:1 soluene:isopropanol by overnight 
heating at 60°C as described previously23. Following tissue solubilisation, one quarter 
of the solubilised liver was collected into a separate tube for further analysis. Tissue 
samples were then bleached with 400 µl 30% hydrogen peroxide and 10 ml Starscint 
added, vortexed and kept at 4°C for 3 days until samples were counted on a 
scintillation counter. 
 
Calculation of pharmacokinetic parameters 
The amount of radiolabel in each plasma sample was converted to ng 
dendrimer equivalents using the specific activity of the 3H-labelled dendrimer. Plasma 
concentrations have been expressed as ng equivalents/ml, however this should be 
viewed with the caveat that this approach assumes that the 3H-content is still 
associated with intact dendrimer. 
The terminal elimination rate constants (k) were obtained by regression 
analysis of the individual post-distributive plasma concentration vs. time profiles. Half 
lives (t½) were determined from ln 2/k. The area under the plasma concentration vs. 
time profiles (AUC0-∞) were calculated using the linear trapezoidal method. The 
extrapolated area (AUCtlast-∞), was determined by division of the last measurable 
plasma concentration (Clast) by k. The initial distribution volume (Vc) was calculated 
by dividing the administered dose by the concentration in plasma at t=0 (Cp0). Post-
distributive volumes of distribution (VDβ) were determined by dividing the 
administered dose by k × AUC0-∞. Plasma clearance (Cl) was calculated by 
dose/AUC0-∞ .  
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Statistics 
Statistical analyses were performed using a 2-way unpaired T-test to compare the 
pharmacokinetic parameters calculated for dendrimers composed of SuN(PN)2 and 
natural L-lysine, for fully PEGylated and half-drugylated dendrimers and for 
comparison of pharmacokinetic parameters between MTX-conjugated PEG570 and 
PEG1100 dendrimers (Generation 3 and 5 only). A 1-way ANOVA and Tukey’s post-
test were used to compare the pharmacokinetic parameters of MTX-conjugated 
dendrimers of differing Generation and PEG chain length for G4 dendrimers. 
Significance was determined at a level of p<0.05.  
 
Results: 
 
Comparison of intravenous pharmacokinetics and disposition of G4(Lys)-(PEG570)32 
and G4(SPN)-(PEG570)32 
 Previous studies have reported the potential utility of poly-lysine dendrimers 
as drug delivery vehicles where the dendrimer scaffold was composed entirely of 
natural L-lysine22, 23, 26. To identify potential differences between PEGylated poly-L-
lysine dendrimers containing an outer generation of natural L-lysine or the 
symmetrical analogue of lysine employed here, the IV pharmacokinetics and 
disposition of symmetrical G4(SPN)-(PEG570)32 was compared to that of the 
previously reported asymmetrical (natural) G4(Lys)-(PEG570)32. The two dendrimers 
were analogous in both molecular weight and in hydrodynamic radius as determined 
by photon correlation spectroscopy (Table 1). A significant difference in the plasma 
residence times of the two dendrimers was evident (Figure 2A, Table 1). The plasma 
half life of G4(SPN)-(PEG570)32 (13.6 h) was significantly longer and plasma 
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clearance (2.7 ml/h) lower than G4(Lys)-(PEG570)32 (Table 1). There were no 
significant differences in the distribution volumes for the two dendrimers. The urinary 
excretion of G4(SPN)-(PEG570)32 was also lower than that of G4(Lys)-(PEG570)32 
(approximately 33 % vs. 43% of injected 3H respectively), however this difference 
was not statistically significant (Table 1). 
 The organ distribution of G4(SPN)-(PEG570)32 (30 h post dose) was similar to 
that of G4(Lys)-(PEG570)32 (Figure 2B) and showed in general low levels of 
radioactivity in all organs collected. Significantly higher levels of G4(SPN)-
(PEG570)32 were recovered in the liver and lungs when compared to G4(Lys)-
(PEG570)32.  
 
Comparison of pharmacokinetics and biodistribution of fully PEGylated and MTX 
conjugated dendrimers  
Comparison of the plasma pharmacokinetic parameters of fully PEGylated 
dendrimers containing a symmetrical analogue of lysine in the outer generation 
(G4(SPN)-(PEG570)32 and G5(SPN)-(PEG570)64) with the respective half PEGylated, 
half ‘drugylated’ constructs of similar MW revealed significant differences between 
the IV pharmacokinetics of the two species (Figure 3). When compared with the fully 
PEGylated species, the more hydrophobic drug conjugated constructs show increased 
plasma clearance and reduced half life (Table 2 and Figure 3), although the increased 
clearance was not reflected in increased targeting towards reticuloendothelial (RES) 
organs. Indeed, the higher plasma clearance of G4(SPN)-(PEG570)16(MTX)16 when 
compared with the fully PEGylated construct appeared to result from retention of the 
dendrimer in the kidneys, especially for the G4 constructs.  
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Plasma pharmacokinetics of methotrexate conjugated dendrimers in Sprague Dawley 
rats  
Figure 4 shows the plasma concentration-time profiles of a series of G3 (Panel 
A), G4 (Panel B) and G5 (Panel C) dendrimers with 50% surface coverage of 
different MW PEGs and 50% surface coverage of methotrexate. Across the dendrimer 
generations, a relationship between PEG chain length and plasma circulation time was 
evident, where increasing the MW of attached PEG decreased clearance and increased 
the elimination half life (Table 3, Figure 5). The data also suggest that systems with 
molecular weights less than approximately 20 kDa were cleared relatively rapidly 
from plasma.   
For the G3 dendrimers (Figure 4A), a small increase in the plasma half life and 
decrease in clearance for the PEG1100 derived dendrimer was evident when compared 
with the PEG570 construct, however, in both cases plasma clearance and urinary 
elimination was relatively rapid, presumably reflecting the lower molecular weight of 
the G3 system (Table 3). 
For the G4 dendrimers (Figure 4B) a good correlation was seen between 
increased PEG chain length, dendrimer molecular weight and the calculated 
pharmacokinetic parameters. Increasing PEG molecular weight increased dendrimer 
MW from 21.1 to 47.2 kDa, decreased clearance from 52 to less than 1 ml/min and in 
turn increased terminal half life from less than 1 h to 34 h (Table 3).  
 For both the G5 dendrimers clearance decreased from 1.5 to 0.6 ml/min with 
increased PEG chain length resulting in an increase in terminal half life from 
approximately 1 day to more than 2 days. For all generation dendrimers examined, 
PEGylation has little effect on volume of distribution. 
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  Across the series of MTX-derived G3-G5 dendrimers examined here and 
including data obtained for similar fully PEGylated dendrimers previously22, a 
relationship was apparent between clearance and MW (Figure 5A) and also between 
terminal half life and MW (Figure 5B) where pronounced reductions in clearance and 
increases in half life were seen for constructs where MW> 20 kDa. 
 
Urinary excretion of MTX conjugated dendrimers 
 The total quantity of injected tritium recovered in urine over the 30 h sampling 
period was approximately 55-65% for both of the G3 dendrimers (Table 3). Whilst 
approximately 10% more injected radioactivity was recovered for the PEG1100 
dendrimer this was not significantly different to the PEG570 dendrimer. Most 
(approximately 50% of the injected dose) of the radioactivity recovered in urine was 
excreted over the initial 8 h post-dose period (see supplementary information). 
 The quantity of injected 3H recovered in the urine of rats administered the G4 
dendrimers G4(SPN)-(PEG570)16(MTX)16 and G4(SPN)-(PEG1100)16(MTX)16 was 
similar (29 vs 23.5% respectively), but considerably lower than that for the G3 
dendrimers with the equivalent PEG chains. There was an even clearer decrease in 
urinary excretion on increasing the PEG chain length on the G4 dendrimer to 2300 Da 
(8.4%, Table 3) possibly suggesting a threshold in the dendrimer size (>20 kDa) 
required to avoid urinary elimination. Similar to the G3 dendrimers, the PEG570 and 
PEG1100 derived G4 dendrimers were relatively rapidly excreted into urine over the 
first 8 h after dosing (see supplementary information). For the G5 dendrimers, very 
little administered 3H was excreted into urine over the sampling period, presumably 
reflecting hindered renal filtration of the large (>40 kDa) PEGylated dendrimers.  
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Size Exclusion Chromatography of Plasma and Urine 
 For the majority of the dendrimers, intact dendrimer was the dominant species 
in plasma and urine (see supplementary information for SEC profiles). The only 
exception was in urine samples collected at later time periods from rats administered 
smaller dendrimers where a proportion of the radiolabel was present as low molecular 
weight species. The absolute quantity of radiolabel in the urine at these time points, 
however, was low when compared to the total proportion of the renally excreted dose. 
  
Biodistribution of MTX conjugated dendrimers in Sprague Dawley rats 
 At the completion of the study major organs were collected to determine the 
pattern of distribution of the injected dendrimers and the results are presented as both 
the tissue mass corrected proportion of radiolabelled dose remaining in each tissue 
(left side of Figure 6) or as the total proportion of injected 3H dose recovered in each 
organ (right side of Figure 6). Whilst uptake into the brain was analysed, the 
radiolabel content was below accurately quantifiable limits (less than 0.1% injected 
3H per g of tissue) in all cases.  
For the G3 dendrimers, the majority of the remaining radiolabel was detected 
in the kidneys (Panels A and B). Small amounts of radiolabel were detected in other 
organs, however the quantity of radiolabel in these organs accounted for less than 1% 
of injected 3H per organ (Panel B). Interestingly, almost 20% of administered 
G3(SPN)-(PEG570)8(MTX)8 was recovered in the kidneys at 30 h compared with only 
2% for the larger G3(SPN)-(PEG1100)8(MTX)8, although similar proportions of 
radiolabel were excreted via the urine for both dendrimers. Size exclusion analysis of 
the supernatant of kidney homogenate revealed that most of the radiolabel retained in 
the kidneys of rats administered the G3 dendrimers was attributed to low molecular 
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weight breakdown products that were also identified in later (8-24h) urine samples 
(see supplementary information). 
 Slightly higher proportions of the G4 dendrimers were recovered in collected 
organs and in particular the liver which contained up to 10% of the administered dose 
at the end of the study. With the exception of G3(SPN)-(PEG570)8(MTX)8, roughly 
similar proportions of radiolabel were recovered for each dendrimer in the liver, 
kidneys, spleen, pancreas, heart and lungs and these accounted for ≤ 1% of the 
injected dose per gram of tissue. This is similar to the biodistribution pattern for the 
fully PEGylated G4(SPN)-(PEG570)32 shown in Figure 2B. Consistent with the data 
obtained for the G3 PEG570 dendrimer, however approximately 23% of the 
administered dose of G4(SPN)-(PEG570)16(MTX)16 was recovered in the kidneys, 
although in this case the radioactivity could be attributed entirely to intact dendrimer 
by SEC (see supplementary information). The proportion of injected dose retained in 
the kidneys decreased sharply to less than 1% for the PEG1100 and PEG2200 derived 
dendrimers. The amount of radiolabel recovered in the liver and kidneys increased 
with increasing PEG chain length, from approximately 0.2% injected 3H/g liver and 
spleen for the PEG570 dendrimer to approximately 1% injected 3H/g for the PEG2300 
dendrimer. 
 The proportion of the G5 dendrimers recovered in the kidneys, pancreas, heart 
and lungs were similar regardless of PEG chain length. Slightly higher proportions of 
the injected dose were recovered in the liver (10-12% of administered 3H) and spleen 
(approximately 2% of administered 3H) when compared with the G4 dendrimers (1-
7% and <1% of administered 3H for liver and spleen respectively).  
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Tumour Biodistribution of G5(SPN)-(PEG1100)32(MTX)32 in rats and mice 
 The tumour disposition of the largest (and longest circulating) dendrimer 
(G5(SPN)-(PEG1100)32(MTX)32) was examined in animals bearing solid rat mammary 
carcinomas (Walker 256) or human adenocarcinoma (HT1080). For direct comparison 
with the pharmacokinetic data obtained in rats, both tumours were generated in 
immunocompromised rats and tumour disposition analysed 2 and 5 days after an IV 
dose. Since the mouse model is also commonly used to study EPR of nanosized 
delivery constructs, the tumour distribution of G5(SPN)-(PEG1100)32(MTX)32 was also 
examined 2 days after an IV dose in mice bearing solid HT1080 tumours. 
 The distribution of G5(SPN)-(PEG1100)32(MTX)32 in rats bearing solid Walker 
256 (Panel A) and HT1080 (Panel B) tumours is shown in Figure 7. Tumour 
accumulation of G5(SPN)-(PEG1100)32(MTX)32 was similar to the degree of uptake 
into the RES organs (approximately 1-2% per g) and was in all cases much greater 
(approximately 5-10 fold) than uptake into control tissues (muscle and fat). Mass 
normalised distribution into the Walker tumour was slightly lower than that seen in 
the HT1080 tumour and the amount retained (per g of tumour) decreased from 2 to 5 
days. The decrease in dendrimer localisation in Walker tumours from 2 to 5 days 
largely reflected an increase in tumour mass since whole tissue accumulation 
remained at 4-5% of the injected dose. In contrast, uptake into the HT1080 tumour 
(per g of tumour) varied less, most likely reflecting the smaller increase in size of the 
HT1080 tumour from 2-5 days. The whole tissue distribution of G5(SPN)-
(PEG1100)32(MTX)32 into HT1080 tumours was approximately 2% of the administered 
dose over the 3 day period. 
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 The disposition of G5(SPN)-(PEG1100)32(MTX)32 in mice bearing HT1080 
tumours is shown in Panel C. Uptake into the HT1080 tumour in mice was relatively 
effective (11% dose per g) and the construct accumulated to a similar extent in the 
tumour and spleen. Tumour uptake was approximately 5-10 fold more effective than 
uptake into muscle or fat in close agreement with the rat data. 
The mass normalised distribution of G5(SPN)-(PEG1100)32(MTX)32 into mouse 
tissues was generally 10 fold higher than that in the rat, reflecting the approximately 
10 fold smaller body mass of mice vs rats (although in the case of uptake into the liver 
the increase in the mouse was only approximately 3 fold). The whole tissue 
distribution of G5(SPN)-(PEG1100)32(MTX)32 into liver and spleen were also lower in 
the mouse than in the rat model (see supplementary information), but the absolute 
extent of accumulation of the dendrimer into HT1080 tumour was the same in both 
species (see supplementary information).  
 
Discussion: 
 
 Previous reports describing the pharmacokinetic behaviour of PEGylated poly-
L-lysine dendrimers have suggested that they may be used to target anticancer drugs 
to solid tumours and to avoid or reduce accumulation in RES organs20. The majority 
of the initial studies in this area, however, have been undertaken with PEGylated 
dendrimers and the potential impact of surface derivatisation of drug has been less 
well defined. The current study was therefore undertaken to characterise the changes 
in the biopharmaceutical profile of PEGylated poly-lysine dendrimers after 
replacement of 50% of the surface PEG groups with a model hydrophobic drug 
(methotrexate) and to further examine the capacity of these systems to promote 
Page 22 of 48
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  23, 18/05/2009 
extended circulation times and tumour uptake in rats and mice. In these studies the 
outer generation of the polylysine dendrimers was composed of a symmetrical 
analogue of lysine (SuN(PN)2) in an attempt to enhance plasma circulation time. A 
fully PEGylated G4 dendrimer containing an outer SuN(PN)2 layer was therefore 
initially compared with data obtained for a similar construct containing natural L-
lysine in the outer layer. The dendrimer constructed with the SuN(PN)2 wedge was 
cleared more slowly than the natural analogue (Figure 2), although the dendrimers 
ultimately showed similar organ deposition profiles. The slower plasma clearance of 
the SuN(PN)2 dendrimer appeared, at least in part, to result from decreased renal 
excretion, although this difference was not statistically significant. We have 
previously reported that the plasma clearance of PEGylated dendrimers is closely 
related to the extent of renal elimination which in turn is a function of molecular 
weight22. The molecular weights and hydrodynamic radii of the dendrimers generated 
using SuN(PN)2 and L-lysine, however, were similar. An explanation for the less avid 
renal clearance of the SuN(PN)2 derived dendrimers is therefore not clear at this time, 
but may suggest that the symmetrical dendrimers are less flexible than dendrimers 
composed of all L-lysine. Structural flexibility has previously been identified to 
impact upon renal and therefore plasma clearance since more flexible structures (such 
as linear polymers) can conform to fit through glomerular filtration slits, whereas the 
filtration of more rigid, globular structures with identical molecular weights is more 
hindered27. Alternatively, the inclusion of the symmetrical SuN(PN)2 may have 
resulted in a change to the orientation of the attached PEG layer, in turn leading to 
differences in renal clearance.  
 Having demonstrated that the circulation time of fully PEGylated poly lysine 
dendrimers may be enhanced by the utilisation of a symmetrical analogue of lysine in 
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the terminal layer, subsequent studies explored the impact of the replacement of 50% 
of the surface PEG chains with a model hydrophobic drug, in this case, methotrexate. 
In general, replacement of 50% of the surface PEG groups with the MTX increased 
plasma clearance and decreased circulatory half life (Table 2, Figure 3) even though 
molecular weight remained relatively constant. In the case of the G4 dendrimers, the 
increase in clearance appeared to result largely from extensive retention of G4(SPN)-
(PEG570)16(MTX)16 in the kidneys. For the G5 dendrimers, the most significant 
difference in biodistribution between the two dendrimers was greater uptake of the 
drug-conjugated dendrimer into the spleen. Removal of 50% surface PEG and 
substitution with acetyl groups (rather than MTX) has previously been shown to result 
in substantially increased plasma clearance of PEGylated polylysine dendrimers25. In 
this case, however, differences could be attributed to a large reduction in MW and 
increase in renal clearance.  
Substitution of surface PEG with MTX therefore increased plasma clearance, 
however construction of dendrimers with a natural (asymmetrical) lysine surface layer 
rather than (SuN(PN)2) helped to off-set this increase in clearance. A larger range of 
50% PEG/50% MTX conjugates were therefore generated employing the symmetrical 
SuN(PN)2 surface in order to better define the impact of drug conjugation on 
clearance and deposition. 
Across the expanded series of 50% PEG, 50% MTX constructs, increasing the 
core size from G3 to G5 or increasing the PEG chain length increased the terminal 
half life and reduced clearance in all cases (Table 3, Figure 4). Interestingly, the 
relationship between the molecular weight of the construct and changes to clearance 
and half life were similar to that seen previously with fully PEGylated natural lysine 
systems, with the exception that for the partly ‘drugylated’ systems, slightly higher 
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plasma clearance was seen when compared with similar sized fully PEGylated natural 
lysine systems (Figure 5). Approximately 10% of the large (up to 59 kDa) MTX-
conjugated dendrimers was recovered in the liver and spleen at the end of the 
experiment, however, RES targeting was lower with the smaller (G3 and G4) 
dendrimers and significantly lower than that reported previously for non-PEGylated 
PAMAM dendrimers28 and anionic PLL dendrimers26. In general, small MW products 
were not evident in plasma samples obtained from animals dosed with the larger 
MTX-PEG dendrimers and those systems modified with higher molecular weight 
PEG chains suggesting that increased generation and PEG chain length confers 
improved plasma and enzymatic stability properties. Small MW products were, 
however, identified in urine and kidney homogenate from rats administered the G3 
dendrimers. Estimation of the proportion of the tritium dose that was recovered in 
urine and kidney homogenate as low MW metabolites reveals that approximately 24, 
14 and 5% of the tritium dose from G3(SPN)-(PEG570)8(MTX)8, G3(SPN)-
(PEG1100)8(MTX)8 and G4(SPN)-(PEG570)16(MTX)16 dosed rats was recovered as 
metabolites in the urine and kidney respectively (estimated based on total radiolabel 
recovery and SEC profiles of urine and kidney homogenate as described in the 
supplementary information). This represents a decrease in apparent metabolism by 
approximately 10% for each 5 kDa increase in MW.  This may reflect either reduced 
affinity for enzymes or reduced distribution into cells and tissues that degrade poly-
lysine dendrimers. It is interesting to note, however, that no evidence of metabolism 
was reported previously for fully PEGylated systems where the PEG chains were 
conjugated to an outer layer of  natural lysine surface dendrimers22. 
 For the purposes of the current investigation, attempts were made to reduce the 
capacity of the MTX-conjugated dendrimers to bind folate transport proteins (such as 
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the folate receptor and the reduced folate carrier) via OTBu protection of the α-
carboxyl group of methotrexate. Previous studies have shown that conjugation of 
large molecules or protecting groups to the alpha-carboxyl group of methotrexate 
greatly reduces the capacity of the antifolate to bind to folate receptors29, inhibit 
dihydrofolate reductase activity30 and inhibit the growth of cancer cells30 in contrast to 
conjugation via the gamma-carboxyl group, which does not appear to greatly affect 
folate binding affinity and anti-tumour activity when compared to methotrexate. 
Methotrexate was therefore conjugated to the dendrimer surface via the gamma-
carboxyl and the alpha carboxyl was tert-butylated in order to reduce the folate 
binding capacity. Despite capping the α-carboxyl group, however, the 50% MTX/50% 
PEG570 G3 and G4 dendrimers were retained in the kidneys in much higher quantities 
than the corresponding 100% PEG constructs (approximately 10 fold higher for the 
G4 construct) suggesting a specific and potentially drug related mechanism of 
interaction for the smaller dendrimers conjugated with the lowest MW PEG. 
Interestingly, for the G3 dendrimer most of the radiolabel retained in the kidney was 
associated with a low MW species that was presumably a breakdown product of the 
dendrimer, whereas radiolabel retained in the kidneys after administration of the 
larger G4 dendrimer was associated almost entirely with intact dendrimer. In the 
kidneys, methotrexate is excreted by passive filtration and active secretory processes 
that involve several folate and non-folate transporters31. Methotrexate is also actively 
reabsorbed in a saturable manner within the proximal tubules by folate-binding 
proteins and the organic anion transporter OAT-K131. A clear explanation for the 
unusual observations regarding uptake into the kidneys is not apparent at this time, 
particularly since significant uptake and potential breakdown in the kidneys has not 
been previously reported for similar macromolecular constructs comprising dextran-
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methotrexate10. However it is possible that the alpha-carboxyl protection employed 
here may not have been sufficient to completely block the interaction of the MTX 
group with folate receptors. In combination with relatively short PEG chains (570 Da) 
this may have allowed the dendrimer or its breakdown products to become entrapped 
within the kidneys by binding to transporters involved with active secretion or 
reabsorption of antifolates. This effect is not evident in systems with higher 
generation dendrimers or longer PEG chains, presumably as a result of reduced 
interaction with folate related receptors or limited initial renal filtration. To this point, 
however, it is unclear why the renal uptake of 3H for the G3, PEG570-MTX system 
was associated with smaller breakdown products whereas the high quantities of 
radiolabel present in the kidneys after administration of the G4 PEG570-MTX system 
is largely associated with intact dendrimer. Studies are ongoing to examine these 
issues in more detail.  
The final aim of the current study was to investigate the potential for 
PEGylated PLL dendrimers to deliver hydrophobic anticancer drugs to solid tumours 
in mice and rats via the EPR effect. To our knowledge this is one of the first direct 
comparisons of tumour targeting in rats and mice and provides interesting insight into 
the pattern of deposition of macromolecular constructs across the two commonly used 
species.  
The HT1080 tumour deposition data for G5(SPN)-(PEG1100)32(MTX)32 in 
mice and rats showed approximately 5 to 10 times higher accumulation in tumour  
tissues when compared with control tissues (fat and muscle).  The extent of tumour 
deposition of the MTX-conjugated dendrimer in mice (approximately 10%/g tumour) 
was consistent with previous mouse deposition data reported by Lee and colleagues 
for much larger polyester dendrimers conjugated with 50% PEG and 50% doxorubicin 
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in a C26 tumour model (approximately 10-15, 6-10 and <1%/g for C26 tumour, RES 
organs and fat and muscle respectively)12and by Lim et al for several PEGylated 
triazine dendrimers in PC3 tumours (approximately 5-8%/g). In the rat model the 
pattern of biodistribution was similar to the mouse, with approximately 5-10 times 
higher accumulation of the dendrimer into both Walker and HT1080 tumours when 
compared with fat and muscle, although in the rat a higher proportion of the absolute 
dose was distributed to the RES organs. The extent of dendrimer uptake into mouse 
tissues when expressed as the % dose/g tissue was approximately 10 fold higher than 
in the rat, however, this does not reflect more effective targeting but rather the smaller 
weight of organs in mice vs rats. Thus, 11% of the injected dose was recovered per 
gram in HT1080 tumours in mice when compared to 1-2% injected dose/g in rats, but 
in both cases this corresponded to the accumulation of approximately 2.3% of the 
dose in the total HT1080 tumour mass. In the larger Walker tumours a larger absolute 
extent of tumour accumulation was evident (4-5% of the dose), but this was again 
consistent with the uptake of approximately 1-2% of the injected dose per g of 
tumour. The current data therefore suggest that rats are an appropriate model for 
investigating tumour deposition of drugs and drug carrier systems and that 
comparable data to that generated in mice can be obtained. Rats have the additional 
advantage that multiple blood samples can be collected providing more reproducible 
pharmacokinetic and biodistribution data. 
 In summary, conjugation of the hydrophobic drug methotrexate to 50% of the 
surface of partly-PEGylated poly-lysine dendrimers increased plasma clearance, but 
this was attenuated by conjugation of PEG and drug to a symmetrical analogue of 
lysine (SuN(PN)2) in the outer layer of the dendrimer. Methotrexate binds folate 
receptors and reduced folate carriers on many tissues and the methotrexate moiety 
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used here was protected at the α-carboxyl group in an attempt to avoid this specific 
interaction. However, it appeared that interaction with folate receptors was not 
completely prevented for dendrimers with shorter (570 Da) PEG chains, since 
extensive retention occurred in the kidneys for the G3 and G4-PEG570 dendrimers. In 
general, increasing dendrimer generation and/or PEG MW decreased plasma 
clearance, increased metabolic stability and decreased renal elimination across the 
dendrimer series. Finally, significant tumour deposition (up to 10 fold higher than 
control tissues) was also demonstrated for the largest 59 kDa dendrimer in both rats 
and mice, providing preliminary data to support the use of partly PEGylated PLL 
dendrimers as vectors for tumour targeting.  
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Table 1. Comparison of plasma pharmacokinetics of G4(Lys)-(PEG570)32 and 
G4(SPN)-(PEG570)32 following IV dosing at 5 mg/kg in rats. Values represent mean ± 
s.d., n=3. ** p<0.01, ***p<0.001 cf. Lys dendrimer. Values for G4(Lys)-(PEG570)32 
are reproduced from a previous publication22. Hydrodynamic radius and PDI 
(parentheses) were estimated by photon correlation spectroscopy. 
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Radius 
(nm) 
t½ (h) Vc (ml) VDβ (ml) Cl (ml/h) % 3H  
dose 
excreted 
in urine 
G4(SPN)-
(PEG570)32 
5.1 
(0.209) 
13.6 ± 
0.3 
13.8 ± 
0.6 
52.2 ± 
4.5 
2.7 ± 0.2 32.7 ± 
7.8 
G4(Lys)-
(PEG570)32 
5.6 
(0.179) 
9.5 ± 
0.3*** 
14.8 ± 
0.4 
65.6 ± 
9.1 
4.8 ± 
0.6** 
42.9 ± 
2.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Plasma pharmacokinetic parameters of G4 and G5 dendrimers possessing an 
outer surface of SuN(PN)2 wedges containing 100% PEG570 or 50% PEG570/50% 
MTX following IV dosing at 5 mg/kg to rats. Values represent mean ± s.d., n=3-4. * 
p<0.05, ** p<0.01, *** p<0.001 cf. fully PEGylated dendrimer. 
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 MW 
(kDa) 
t½ (h) Vc (ml) VDβ (ml) Cl (ml/h) %  3H 
dose 
excreted 
in urine 
Generation 4 
(PEG570)32 22.2 13.6 ± 0.3 13.8 ± 0.9 52.2 ± 3.2 2.7 ± 0.1 32.7 ± 7.8 
(PEG570)16 
(MTX)16 
21.1 0.4 ± 
0.0*** 
23.3 ± 
1.4*** 
32.8 ± 
4.4** 
51.9 ± 
2.3*** 
29.0 ± 3.4 
Generation 5 
(PEG570)64 47.5 37.2 ± 1.7 13.0 ± 0.6 22.4 ± 1.1 0.4 ± 0.0 5.7 ± 0.5 
(PEG570)32 
(MTX)32 
42.2 23.7 ± 6.2* 16.2 ± 
0.1*** 
52.1 ± 
16.4* 
1.5 ± 
0.1*** 
2.4 ± 0.5** 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Pharmacokinetic parameters of partly PEGylated dendrimers conjugated with 
50% MTX following IV dosing at 5 mg/kg to rats. Values represent mean ± s.d., n=3-
4.  
 
 MW 
(kDa) 
t½ (h) Vc (ml) VDβ (ml) Cl (ml/h) % 3H dose 
excreted  
in urine 
G3(SPN) 
(MTX)8 
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(PEG570)8 10.5 0.1 ± 0.0 
 
16.2 ± 0.7 28.4 ± 4.7 133 ± 19 55.7 ± 8.6 
(PEG1100)8 14.8 0.2 ± 0.01 19.6 ± 6.1 25.9 ± 7.0 98.5 ± 29.3 64.1 ± 4.7 
G4(SPN) 
(MTX)16 
      
(PEG570)16 21.1 0.4 ± 0.0d 23.3 ± 1.4a 32.8 ± 4.4 51.9 ± 2.3a 29.0 ± 3.4a 
(PEG1100)16 29.6 21.0 ± 1.9ac 14.4 ± 1.7 41.7 ± 4.8 1.4 ± 0.1a 23.5 ± 17.7a 
(PEG2200)16 47.2 34.1 ± 1.3cd 13.3 ± 0.6cd 29.5 ± 2.7ad 0.6 ± 0.1cd 8.4 ± 1.4d 
G5(SPN) 
(MTX)32 
      
(PEG570)32 42.2 23.7 ± 6.2ab 16.2 ± 0.1b 52.1 ± 16.4 1.5 ± 0.1ab 2.4 ± 0.5ab 
(PEG1100)32 59.2 51.3 ± 3.2abc 16.0 ± 1.1 43.1 ± 1.5a 0.6 ± 0.0ac 1.2 ± 0.1abc 
a
 significant difference (p<0.05) cf. equivalent G3 dendrimer 
b
 significant difference (p<0.05) cf. equivalent G4 dendrimer 
c
 significant difference (p<0.05) cf. equivalent Generation PEG570 dendrimer 
d
 significant difference (p<0.05) cf. equivalent Generation PEG1100 dendrimer 
 
 
 
 
 
 
 
 
 
 
Scheme legends: 
 
Scheme 1. i. 1 with N-(Benzyloxycarbonyl)-3-bromopropylamine in TEA/DMF; ii. 2 
with succinic anhydride in toluene to give 3a; iii. 3a  with DCC and DMAP in 
DCM/EtOH to give 3b; iv. 3b  with ammonium formate and Pd/C in DMF/water to 
give 4a; v. 4a with PEG-NHS ester in TEA/DCM to give 4b; vi. 4b in TFA/DCM to 
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give 5a; vii. 5a with MTX(-α-OtBu), DIPEA, and pyBOP in DMF to give 5b; viii 5b 
with NaOH in THF/water to give 5c. 
 
Scheme 2. i. 1 with SuN(PN)2 (PEG570)(MTX-α-OtBu) wedge, DIPEA, and pyBOP 
in DMF to give 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Legends: 
 
Figure 1. Schematic diagram of poly-L-lysine dendrimers comprising 50% PEG (P) 
and 50% MTX linked to surface amine residues (M) associated with SuN(PN)2  (SPN) 
groups in the outer layer (A) and of surface SPN(PEG)(MTX) units linked to G2-4 
polylysine scaffolds (producing dendrimers of generation 3-5, B). 
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Figure 2. Plasma concentration-time profile of G4(Lys)-(PEG570)32 (closed symbols) 
and G4(SPN)-(PEG570)32 (open symbols) following 5 mg/kg IV administration to rats 
(Panel A). Distribution of injected 3H 30 h after IV administration of G4(Lys)-
(PEG570)32 (closed bars) and G4(SPN)-(PEG570)32 (open bars) (Panel B). Data 
represent mean ± s.d. (n=3). * p<0.05 cf. ‘symmetrical’ dendrimer. Data for G4(Lys)-
(PEG570)32 are reproduced from a previous publication.22 
 
Figure 3. Plasma concentration-time profiles (Panels A and B) and tissue distribution 
(Panels C and D) in rats administered 5 mg/kg of G4 (Panels A and C) or G5 
(Panels B and D) PLL dendrimers containing outer SuN(PN)2 wedges containing 
100% PEG570 (closed symbols) or 50% PEG570/50% MTX (open symbols). Data 
represent mean ± s.d. (n=3-4). 
 
Figure 4. Plasma concentration-time profiles of G3 (Panel A), G4 ( Panel B) and G5 
(Panel C) MTX conjugated dendrimers. Attached PEG groups are PEG570 (closed 
circles), PEG1100 (open circles) and PEG2200 (closed triangles). Data represent mean ± 
s.d. (n=3-4). 
 
Figure 5. Correlation between dendrimer MW and plasma clearance (Panel A) and 
terminal half life (Panel B) for G3-G5 MTX-conjugated dendrimers containing an 
outer generation of SuN(PN)2 (closed symbols) and similar fully-PEGylated 
dendrimers comprising an all L-lysine outer generation (open symbols, reproduced 
from Kaminskas et al, 200822). MW was determined by mass spectrometry as shown 
in the supplementary information. Data represent mean ± s.d. (n=3-4). 
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Figure 6. Distribution of injected 3H in major organs 30-168 hours after intravenous 
administration of MTX conjugated 3H-dendrimers (5 mg/kg) to rats. Panel A - mass 
normalised % of injected radiolabel retained in each organ 30 h after administration of 
G3 dendrimers. Panel B - % of injected radiolabel retained in each organ 30 h after 
administration of G3 dendrimers. Panel C - mass normalised % of injected radiolabel 
retained in each organ 30, 96 or 120 h after administration of G4, PEG570, PEG1100 or 
PEG2300 dendrimers respectively. Panel D - % of injected radiolabel retained in each 
organ 30, 96 or 120 h after administration of G4, PEG570, PEG1100 or PEG2300 
dendrimers respectively. Panel E - mass normalised % of injected radiolabel retained 
in each organ 120 or 168 h after administration of G5, PEG570 or PEG1100 dendrimers 
respectively. Panel F - % of injected radiolabel retained in each organ 120 or 168 h 
after administration of G5, PEG570 or PEG1100 dendrimers respectively. Black bars 
represent data for PEG570 dendrimers, white bars depict data for PEG1100 dendrimers 
and grey bars represent data for the PEG2300 dendrimer. Data are represented as mean 
± s.d. (n=3-4). 
 
Figure 7. Distribution of G5(SPN)-(PEG1100)32(MTX)32 2 days (closed bars) or 5 days 
(open bars) after IV administration to athymic nude rats bearing solid Walker 256 
(Panel A) or HT1080 (Panel B) tumours or in mice bearing HT1080 tumours (Panel 
C). Data are expressed as mean ± s.d. (n=3) of the % injected dose per g tissue. Rats 
received an IV dose when tumour reached approximately 1000 mm3 and mice 
received an IV dose when tumours reached approximately 100 mm3. 
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